| Literature DB >> 31947853 |
Eric de Groot1,2, Lisa Schweitzer3, Stephan Theis3.
Abstract
Hyperglycemia is linked to impaired arterial endothelial function (EF), an early sign of cardiovascular disease. We compared the efficacy of low-glycemic index isomaltulose (Palatinose™) with that of sucrose in modulating EF, as assessed by flow-mediated dilation (FMD). In this double-blinded cross-over study, 80 overweight mildly hypertensive subjects were randomized to receive 50 g of either isomaltulose or sucrose. On two non-consecutive days, brachial artery ultrasound FMD scans were obtained prior to and hourly (T0-T3) after carbohydrate load. Blood was drawn immediately after scanning. Glucose and insulin levels were analyzed. Overall, the FMD decrease was attenuated by isomaltulose compared to sucrose (ΔFMD = -0.003% and -0.151%; p > 0.05 for the interaction treatment x period). At T2, FMD was significantly higher after isomaltulose administration compared to that after sucrose administration (FMD = 5.9 ± 2.9% and 5.4 ± 2.6%, p = 0.047). Pearson correlations between FMD and blood glucose showed a trend for a negative association at T0 and T2 independently of the carbohydrate (r-range = -0.20 to -0.23, p < 0.1). Sub-analysis suggested a lower FMD in insulin-resistant (IR) compared to insulin-sensitive subjects. Isomaltulose attenuated the postprandial decline of FMD, particularly in IR persons. These data support the potential of isomaltulose to preserve the endothelial function postprandially and consequently play a favorable role in cardiovascular health.Entities:
Keywords: carbohydrates; cardiovascular health; endothelial function; glycemic index; insulin resistance; isomaltulose
Year: 2020 PMID: 31947853 PMCID: PMC7019610 DOI: 10.3390/nu12010141
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Outline of the study protocol. FMD, flow-mediated dilation; ISO, citrus drink containing 50 g of isomaltulose; SUC, citrus drink containing 50 g of sucrose.
Baseline characteristics of the study population before the first intervention day (n = 78).1,2.
| Gender, % | 34% Females, 66% Males |
|---|---|
| Age, years | 46.6 ± 8.4 |
| Height, cm | 174.4 ± 9.8 |
| BMI, kg/m² | 28.9 ± 2.6 |
| Blood pressure (BP), mmHg | |
| Systolic BP | 137.8 ± 5.0 |
| Diastolic BP | 88.2 ± 3.6 |
| Fasting FMD, % | 5.8 ± 2.5 |
| Fasting blood glucose, mmol/L | 4.9 ± 0.5 |
| Fasting insulin, pmol/L | 61.8 ± 28.0 |
| HOMA index | 1.9 ± 1.0 |
| Insulin sensitivity 3 | 79% insulin sensitive, 21% insulin resistant |
1 Values are reported as mean ± SD. 2 FMD, flow-mediated dilation; HOMA, homeostasis model assessment. 3 Classified according to the HOMA on their first intervention day: HOMA < 2.5 = insulin-sensitive; HOMA ≥ 2.5 = insulin-resistant; BMI, body mass index.
Figure 2Basal (T0) and postprandial (T1–T3) FMD (A), blood glucose (B), and insulin levels (C) following the ingestion of isomaltulose () and sucrose (). All values are reported as mean ± SD; T0 = 0 min, T1 = 60 min, T2 = 120 min, T3 = 180 min; * Significant difference between isomaltulose and sucrose; paired t test: p < 0.05.
Change in flow-mediated dilation from baseline in the subjects classified as insulin-sensitive and insulin-resistant according to HOMA index 1,2.
| FMD Change from Baseline (T0, %) | |||||
|---|---|---|---|---|---|
| Time Points | Insulin Sensitivity | Isomaltulose | Sucrose | ||
|
|
| −0.16 ± 2.02 | 0.285 | −0.74 ± 1.92 | 0.107 |
|
| −0.81 ± 1.96 | −1.74 ± 2.54 | |||
|
|
| 0.34 ± 2.33 | 0.180 | −0.23 ± 1.92 | 0.435 |
|
| −0.62 ± 2.35 | −0.68 ± 2.17 | |||
|
|
| 0.12 ± 2.36 | 0.794 | 0.65 ± 2.10 | 0.692 |
|
| −0.07 ± 2.54 | 0.40 ± 2.35 | |||
1 FMD, flow-mediated dilation; HOMA, homeostasis model assessment; IR, insulin resistant (HOMA ≥ 2.5); IS, insulin sensitive (HOMA < 2.5). 2 Values are reported as mean ± SD. 3 No significant differences between IR and IS subjects; unpaired t test: p > 0.05.